Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Ligong Nie"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract To explore the role of bronchoscopy for the assessment of checkpoint inhibitor pneumonitis (CIP), a retrospective single-center study was conducted to assess patients diagnosed with CIP at grade 2 or above and also underwent bronchoscopy bet
Externí odkaz:
https://doaj.org/article/aff99d2f6e0d483d8c1d71592a46ad1d
Autor:
Jieran Long, Xuefei Li, Lin Wu, Guohua Yu, Aimin Zang, Yanqiu Zhao, Jinsheng Shi, Ligong Nie, Xuan Zhao, Jian Fang
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Purpose To evaluate the safety, tolerability, and preliminary efficacy of multiple doses of pegylated irinotecan (JK1201I) as a second‐line monotherapy for treating small‐cell lung cancer (SCLC) patients. Methods According to the “3 +
Externí odkaz:
https://doaj.org/article/c0eff1742b674608ab739db3cf6ba979
Autor:
Xiang Zhao, Yuan Cheng, Cuiyan Guo, Ligong Nie, Qi Zhang, Meng Zhang, Kunyan Sun, Guangfa Wang
Publikováno v:
Health Science Reports, Vol 7, Iss 5, Pp n/a-n/a (2024)
Abstract Background and Aims Immune checkpoint inhibitors (ICIs) across multiple treatment lines have not yet been evaluated comprehensively. The purpose of this research was to investigate whether or not continuous cross‐line ICIs therapy is effec
Externí odkaz:
https://doaj.org/article/c0356fab5fb94e639e0fe17f24d8cc4e
Autor:
Bo Zhang, Xingya Li, Zhiyong Ma, Shucai Zhang, Xia Song, Hongjun Gao, Liqun Gong, Yi Hu, Mengzhao Wang, Da Jiang, Cuiying Zhang, Xuedong Yuan, Baoshan Cao, Peng Zhang, Ligong Nie, Yuhui Zhang, Xiaoyan Chen, Lei Han, Wenqiang Wei, Yuankai Shi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 11, Pp 1684-1690 (2022)
Abstract Background Pain is a fearful yet common symptom among lung cancer patients. This multicenter, cross‐sectional study was conducted to examine the current status of pain prevalence and management in lung cancer patients in northern China. Me
Externí odkaz:
https://doaj.org/article/0194832f58844c2c8b9130d6c89a1f18
Publikováno v:
Thoracic Cancer, Vol 13, Iss 9, Pp 1419-1422 (2022)
Abstract A therapeutic option for advanced non‐small‐cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) resistance is a clinical challenge. The clinical outcomes of pembrolizumab in th
Externí odkaz:
https://doaj.org/article/9e382ea8f41346d4819f7377f4fc2acc
Autor:
Huan Hou, Cuiyan Guo, Chengli Que, Ligong Nie, Qi Zhang, Hong Zhao, Lin Nong, Wei Ma, Qian Wang, Zeyin Liang, Bingjie Wang, Jing Ma, Guangfa Wang
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Intrapulmonary arteriovenous shunts is rare seen in a patient without lung involvement. Case presentation This is the first report of reversible intrapulmonary arteriovenous shunts secondary to extrapulmonary lymphoma as one initi
Externí odkaz:
https://doaj.org/article/2b88739cb77c4172959c4a0239c61184
Publikováno v:
Thoracic Cancer, Vol 12, Iss 20, Pp 2803-2806 (2021)
Abstract The efficacy of immunotherapy in non‐small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations is not well clarified, even though immunotherapy has brought revolutionary improvements in EGFR wild‐type
Externí odkaz:
https://doaj.org/article/17d444e7409341fc96fe9d47ffccdcb2
Publikováno v:
Thoracic Cancer, Vol 12, Iss 12, Pp 1927-1930 (2021)
Abstract Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐
Externí odkaz:
https://doaj.org/article/a03ba405bec54472a1e8e79170d7f040
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 690-692 (2021)
Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistan
Externí odkaz:
https://doaj.org/article/9f0c37dea44d4ce2bd173c46166038b5
Publikováno v:
Thoracic Cancer, Vol 10, Iss 7, Pp 1576-1580 (2019)
Background Intravenous infusion of Endostar for three to four hours per day for 14 days reduces patient compliance and affects quality of life. Continuous intravenous infusion (CI) represents a novel method of administration; however, it is unclear w
Externí odkaz:
https://doaj.org/article/f0146c1849844ad4b9bc90402478d2b6